l-Carnitine status in end-stage renal disease patients on automated peritoneal dialysis

Effect of an l-Carnitine–Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial

(2013) Mario Bonomini et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Serum Metabolite Concentrations and Decreased GFR in the General Population

(2012) Oemer-Necmi Goek et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of hemodialysis session on the dynamics of carnitine ester profile changes in l-carnitine pretreated end-stage renal disease patients

(2012) Botond Csiky et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Time Course of Peritoneal Function in Automated and Continuous Peritoneal Dialysis

(2012) W. M. Michels et al.   PERITONEAL DIALYSIS INTERNATIONAL

Disruption of mitochondrial homeostasis in organic acidurias: insights from human and animal studies

(2011) Moacir Wajner et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

l-Carnitine is an osmotic agent suitable for peritoneal dialysis

(2011) Mario Bonomini et al.   KIDNEY INTERNATIONAL

Biocompatible Peritoneal Dialysis Solutions: Do We Have One?

(2010) K. Chaudhary et al.   Clinical Journal of the American Society of Nephrology

Carnitine, mitochondrial function and therapy☆

(2009) Victor A. Zammit et al.   ADVANCED DRUG DELIVERY REVIEWS

False-positive newborn screening mimicking glutaric aciduria type I in infants with renal insufficiency

(2009) Julia B. Hennermann et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Carnitine in metabolic disease: Potential for pharmacological intervention

(2008) A ARDUINI et al.   PHARMACOLOGY & THERAPEUTICS